Business model; Merger & Acquisitions; cross-sectorial collaborations and partnerships; hurdles; innovations; macro and micro changes; stakeholders
Abstract :
[en] INTRODUCTION:
Due to changing macro and micro factors, expiring patents and falling net income, pharmaceutical companies need to rethink their vertical business model. The trend shows cross-sectorial partnerships and consolidation to remain and compete on the market. Areas covered: Quantitative research interviewing a target group of 25 key executives from small, mid and large global pharmaceutical companies rounded with qualitative literature research completing the analysis. Expert commentary: Uncertainty in the industry due to changing external factors i.e. pricing pressures, regulations or an economic slowdown, slowing down innovations and new drug outcomes. Pharmaceutical companies understand the existing hurdles, and are critically optimistic implementing new business models. Also, various stakeholders are included in the value chain due to their growing importance.
CONCLUSION:
During the next years, the industry will be restructured from volume towards value, and only pharmaceutical companies' clairaudient and reciprocate to the changes with an out-off the box thinking will be able to resist on the market. Small biotech companies should focus on research, and big pharmaceutical companies entering at development focusing on the process until the distribution. This execution business recommendation would enable the best know-how at the right point, mitigating the risk and enhancing the patient outcomes.
Disciplines :
Pharmacy, pharmacology & toxicology Public health, health care sciences & services
Bruyère, Olivier ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Language :
English
Title :
Micro Factors Bringing the Pharmaceutical Industry to a Seismic Shaking A Qualitative Research
Publication date :
2017
Journal title :
Expert Review of Pharmacoeconomics and Outcomes Research
Investopia. Business Model. 2017 Jan 01 [cited 2017 Feb 01]. Available from:http://www.investopedia.com/terms/b/businessmodel.asp
Light DW, Kantarijian H., Market spiral pricing of cancer drugs. Cancer. 2013 Sep 03;sec. 119-3900-2 119:3900–3902.•• Of considerable interest as the paper analyses the year-on-year increase of prices for cancer drugs showing that the 2 bn development cost is more an industry myth than the real net costs a company has, with consequence the hyperbolism pricing.
Prescribe International May. New drugs, new indications in 2015:little progress, and threats to access to quality healthcare for all. Prescrire International. 2016 May 31;25(171):137–139.
Bradshaw B. Pharmaceuticals firms braced for a year of rampant M&A. The Telegraph. 2017 Jan 09. sec. A. p. 1
Reuters. GSK and Novartis complete deals to reshape both drugmakers. 2015 Mar 02 [cited Feb 12 2017]. Available from:http://www.telegraph.co.uk/finance/newsbysector/pharmaceuticalsandchemicals/11444023/GSK-and-Novartis-complete-deals-to-reshape-both-drugmakers.html
Bradshaw B. GlaxoSmithKline and Google’s Verily to Invest GBO540m in Joint UK Research Centre. The Telegraph. 2016 Aug 01. sec. A.p. 1.
Buckley JW, Chiang H. Research methodology and business decisions. National Association of Accountants. 2014 Sep 01. sec. A. pp. 87–88
Silverman D. Doing qualitative research. California US:Sage Publications. 2013 Dec 01. sec. A. 200–213.
Mays N, Pope C. Qualitative research in health care. Assessing quality in qualitative research. BMJ. 2000 Jan 01 sec. A. 20:312–320.
Malmström R, Godman B, Diogene E., Dabigatran–a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Front Pharmacol. 2013 May 14 sec. A. 4–39.
Godman B, Malmström R, Diogene E., Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?. Expert Rev Clin Pharmacol. 2015 Jan 8;8:77–94. sec. A.• Of considerable interest as it shows that governments needs to enhance the requirements to enter the market and make drugs affordable and available. The entry process should always be based on the three pillar model:pre-, peri- and post-launch.
O’Neill J. Securing new drugs for future generations:the pipeline of antibiotics. The review on antimicrobial resistance. 2015 May 31 [cited 2017 June 14]. Available from:https://amr-review.org/sites/default/files/SECURING%20NEW%20DRUGS%20FOR%20FUTURE%20GENERATIONS%20FINAL%20WEB_0.pdf
The Pharmaletter. An all-time record year for pharma/biotech M&A in 2015. 2016 Jan 07 [cited 2017 Feb 11]. Available from:https://www.thepharmaletter.com/article/an-all-time-record-year-for-pharma-biotech-m-a
Abboud C, Berman E, Cohen A. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs:from the perspective of a large group of CML experts. Blood. 2013 Apr 23;sec. A 121(22):4439–4442.• Of interest as it considers the moral discussion what price drugs should have.
Dierks R, et al. Macro-economic factors influencing the architectural business model shift in the pharmaceutical industry. Expert Rev Pharmacoecon Outcomes Res. 2016 Oct 05;sec. A. 1:1–6.•• Of considerable interest as it focuses on the macro economic factors that change the pharmaceutical industry
AbbVie. AbbVie to expand oncology presence through acquisition of Stemcentrx and its novel, late-stage rova-T compound for small cell lung cancer. 2016 Apr 28 [cited 2017 Feb 11]. Available from:https://news.abbvie.com/news/abbvie-to-expand-oncology-presence-through-acquisition-stemcentrx-and-its-novel-late-stage-rova-t-compound-for-small-cell-lung-cancer.htm
Financial Times. Johnson & Johnson to buy Swiss biotech Actelion for USD 30bn. 2017 Jan 29 [cited 2017 Jan 31]. Available from:https://www.ft.com/content/b3b98348-e396-11e6-8405-9e5580d6e5fb• Of interest, showing the interest from big pharma companies to acquire small niche players.
The Pharmaletter. 2017 M&A outlook for mid-market pharma:dealmaking will continue to be a key growth strategy. 2016 Dec 21 [cited 2017 Feb 11]. Available from:https://www.thepharmaletter.com/article/2017-m-a-outlook-for-mid-market-pharma-dealmaking-will-continue-to-be-a-key-growth-strategy
Hirschler B. Trump tax cuts could mean more Novartis investment in U.S. Reuters. 2017 Jan 18. sec. A. p. 1.
BMI Research. Growth of the Global Pharmaceutical Market. Aug 5 2010 [cited 2017 Mar 25]. Available from:http://www.bmiresearch.com/searchbox